fallypride

dopamine receptor antagonist

Also Known As:

5-(3-fluoropropyl)-2,3-dimethoxy-N-(((2S)-1-(2-propenyl)-2-pyrrolidinyl)methyl)benzamide; Benzamide, 5-(3-fluoropropyl)-2,3-dimethoxy-N-(((2S)-1-(2-propen-1-yl)-2-pyrrolidinyl)methyl)-

Networked: 42 relevant articles (2 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Myin-Germeys, Inez: 6 articles (01/2020 - 01/2013)
2.	Ceccarini, Jenny: 5 articles (01/2020 - 01/2013)
3.	Christian, Bradley T: 4 articles (01/2022 - 07/2006)
4.	Mukherjee, Jogeshwar: 4 articles (01/2022 - 07/2006)
5.	Cumming, Paul: 4 articles (12/2018 - 03/2010)
6.	Gründer, Gerhard: 4 articles (01/2018 - 05/2006)
7.	Vernaleken, Ingo: 4 articles (01/2018 - 05/2006)
8.	Bartenstein, Peter: 4 articles (01/2016 - 05/2006)
9.	Collip, Dina: 4 articles (01/2016 - 01/2013)
10.	Hernaus, Dennis: 4 articles (01/2016 - 01/2013)

Related Diseases

1.	Huntington Disease (Huntington's Disease) 08/05/2019 - "Improved synthesis of [18F] fallypride and characterization of a Huntington's disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors." 01/01/2021 - "Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study."
2.	Pain (Aches) 01/01/2016 - "Positron emission tomography (PET) with [(18)F]fallypride (FAL) was used to assess changes in DA during a working memory challenge relative to a baseline task, and to test for associations between baseline D2/D3 availability and experimental pain measures. " 01/01/2016 - "Here we used a human thermal pain model to compare self-reports of expected, concurrent, and recalled efficacy of a topical placebo analgesic, and tested associations of the three measures of efficacy with changes in dopamine D2/D3 receptor availability in brain using [(18)F]fallypride with positron emission tomography (PET). "
3.	Schizophrenia (Dementia Praecox) 01/01/2018 - "The results of this study demonstrate that lower fallypride binding potential in patients with schizophrenia may be associated with better performance. " 10/01/2010 - "We used positron emission tomography with [(18)F]fallypride to evaluate D(2)/D(3) receptors in both striatal and extrastriatal regions in schizophrenia. " 07/01/2006 - "The thalamus of patients with schizophrenia had lower [F-18]fallypride BP than normal controls and this was the brain area with the greatest difference (range -8.5% to -27.2%). " 12/01/2018 - "Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [18 F]fallypride PET and functional MRI study." 09/01/2018 - "The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride."
4.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2018 - "We performed a DA D2/3 receptor [18F]fallypride positron emission tomography scan during a probabilistic reinforcement learning task in 16 healthy first-degree relatives of patients with psychosis and 16 healthy volunteers, followed by a 6-day ecological momentary assessment study capturing reward-oriented behavior in the everyday life. " 02/01/2015 - "Healthy first-degree relatives of individuals with a psychotic disorder (N = 14) and healthy controls (N = 11) participated in (a) a psychosocial [18F]fallypride PET stress paradigm and (b) an experience sampling study, using a structured diary approach. " 01/01/2016 - "We explored the combined effects of childhood adversity and adult stress by exposing 12 unmedicated individuals with a diagnosis of non-affective psychotic disorder (NAPD) and 12 healthy controls (HC) to psychosocial stress during an [18F]fallypride positron emission tomography. " 01/01/2013 - "A combined sample of healthy controls and healthy first-degree relatives of psychosis patients (n = 26) were subjected to an [(18)F]fallypride Positron Emission Tomography scan. " 01/01/2014 - "Fourteen healthy first-degree relatives of patients with a diagnosis of psychotic disorder and 10 control subjects underwent a single dynamic positron emission tomography (PET) scanning session after intravenous administration of 183.2 (SD = 7.6) MBq [(18)F]fallypride. "
5.	Disease Progression 08/05/2019 - "These results are in line with clinical findings in HD patients, suggesting [18F] fallypride PET imaging has potential as a quantitative translational approach to monitor disease progression in preclinical studies." 01/01/2023 - "[18 F]Fallypride and [18 F]FDG are PET imaging biomarkers of mHTT-mediated disease progression that can be used as noninvasive outcome measures in future therapeutic studies with this AAV-mediated HD macaque model. "

Related Drugs and Biologics

1.	Dopamine (Intropin)
2.	Analgesics (Analgesic Drugs)
3.	Methylphenidate (Ritalin)
4.	Aripiprazole (Abilify)
5.	Dopamine D2 Receptors (Dopamine D2 Receptor)
6.	Biomarkers (Surrogate Marker)
7.	Antipsychotic Agents (Antipsychotics)
8.	Opiate Alkaloids
9.	Prolactin
10.	Amisulpride (Solian)

Related Therapies and Procedures

1.	Intravenous Administration